Welcome to our dedicated page for Mimedx Group news (Ticker: MDXG), a resource for investors and traders seeking the latest updates and insights on Mimedx Group stock.
MiMedx Group, Inc. (NASDAQ: MDXG) is a regenerative medicine and advanced wound care company whose activities generate frequent news across clinical, regulatory, financial, and legal fronts. The company develops and markets placental tissue–based allografts and other biomaterial products used in chronic and hard-to-heal wounds, burn care, and selected surgical applications, and it regularly updates investors and clinicians on developments affecting these businesses.
News about MiMedx often includes announcements of new product launches and portfolio expansions, such as the introduction of EPIXPRESS, a lyophilized human placental-based allograft, and the exclusive U.S. distribution agreement for RegenKit Wound Gel. The company also highlights clinical and scientific milestones, including peer-reviewed publications on Purion processed human amniotic membrane allografts and interim results from randomized controlled trials like the CAMPAIGN study evaluating EPIEFFECT in nonhealing diabetic foot ulcers.
Investors following MDXG can expect regular earnings releases, conference call details, and commentary on reimbursement policy changes, particularly regarding Medicare rules for skin substitutes and advanced wound care products. MiMedx uses press releases to discuss how reimbursement reforms may affect its market and to describe its operational and commercial positioning.
In addition, MiMedx appears in news related to legal and regulatory matters, including litigation with former employees and references to FDA communications on specific products. Coverage may also include the company’s participation in investor conferences and clinical meetings such as the Symposium on Advanced Wound Care. For those tracking MDXG, this news stream provides insight into product performance, scientific evidence, regulatory context, and corporate strategy over time.
MiMedx Group, Inc. (MDXG) will release its financial results for Q4 2021 on February 28, 2022, after market close. A webcast and conference call will follow at 5:00 p.m. ET for management to discuss these results. The company specializes in placental biologics, providing allografts for treating acute and chronic wounds, and has a strong pipeline for musculoskeletal conditions. With over 2 million allografts supplied, MiMedx focuses on innovative healthcare solutions.
MiMedx Group, Inc. (MDXG) has launched a pivotal Phase 3 clinical study program for its micronized dehydrated Human Amnion Chorion Membrane (mdHACM) targeting knee osteoarthritis (KOA) with a potential commercial launch in late 2026. The company aims for double-digit growth in 2022, driven by treatment transformations and global expansion, including the mid-2022 launch of EPIFIX® in Japan. The 2022 outlook includes a revenue growth target of 11%-14% and an increase in R&D spending from $17 million to $22 million, despite a slight dip in gross margins due to competitive dynamics.
Mariotta, Ga. - January 4, 2022 - MiMedx Group, Inc. (Nasdaq: MDXG) announced participation in the H.C. Wainwright BioConnect Virtual Conference from January 10-13, 2022. CEO Timothy R. Wright, CFO Peter M. Carlson, and EVP Robert B. Stein will engage in a pre-recorded fireside chat available on the company's website starting January 10 at 7:00 AM ET. MiMedx specializes in placental biologics, providing allografts for treating non-healing wounds and musculoskeletal conditions, utilizing proprietary methods to ensure quality and efficacy.
MARIETTA, Ga., Dec. 22, 2021 – MiMedx Group, Inc. (Nasdaq: MDXG) announced that CEO Timothy R. Wright and CFO Peter M. Carlson will present at the 40th Annual J.P. Morgan Healthcare Conference on January 12 at 5:15 PM EST. Institutional investors can schedule virtual meetings with management through their J.P. Morgan representatives. A live webcast will be available on the Company’s website, with a replay accessible for 30 days post-presentation. MiMedx is a leader in placental biologics, focusing on non-healing wounds and musculoskeletal conditions.
MIMEDX Group, Inc. (MDXG) announced key insights during its virtual Investor Day, focusing on its KOA clinical program and robust commercial growth potential. The company anticipates initiating Phase 3 trials for its Knee Osteoarthritis candidate in 2022, with a Biologics License Application expected by late 2025. MIMEDX raised its adjusted net sales outlook for 2021 to $253-$258 million, surpassing previous estimates. The company's commercial strategy targets sustainable growth of 11-14% in several underpenetrated markets, driven by product innovation and global expansion initiatives.
MIMEDX (Nasdaq: MDXG) plans to host a virtual Investor Day on December 7, 2021, at 9:00 a.m. ET. CEO Timothy R. Wright will share insights from their knee osteoarthritis clinical study, highlighting significant outcomes in WOMAC scores with p-values below 0.05 at three months and below 0.01 at six months. The event will also cover growth strategies and advancements in their commercial business. Key speakers will include executives and third-party experts discussing the musculoskeletal pipeline and market opportunities. Registrations can be made using the access code ‘MDXG.’
MiMedx Group, Inc. (Nasdaq: MDXG) announced that Timothy R. Wright, CEO, and Rohit Kashyap, Ph.D., Chief Commercial Officer, will present at the Piper Sandler 33rd Annual Healthcare Conference from November 29 to December 2, 2021. The presentation will be available on-demand starting November 22 at 10:00 AM ET on the Company’s website.
MiMedx specializes in regenerative medicine using amniotic tissue, aiming to address acute and chronic wounds, and has supplied over two million allografts to date.
MiMedx Group, Inc. (Nasdaq: MDXG) announced a peer-reviewed study demonstrating that its PURION® processed dHACM (EPIFIX®) provides a significantly lower risk for infection and scarring compared to traditional autologous tissue methods in Mohs micrographic surgeries. The study, involving 286 patients, revealed those using placental allografts were 12 times less likely to experience post-surgical infections and 19 times less likely to have unacceptable scarring. The findings validate the use of placental allografts as a safer reconstruction alternative, particularly for older patients with multiple skin cancer surgeries.
MiMedx Group reported third quarter 2021 net sales of $63.1 million, a slight decline from $64.3 million in 3Q20. Adjusted net sales of $62.8 million reflect a 13% increase in core portfolio sales year-over-year. The company recorded a net loss of $2.3 million, significantly less than $19.4 million in the previous year. Adjusted EBITDA was $6.8 million. The outlook for 2021 projects adjusted net sales between $245 million to $255 million, signaling potential growth in surgical applications and ongoing clinical efforts.
Marietta, Ga. — MiMedx Group (Nasdaq: MDXG) announced its participation in upcoming virtual investor conferences. CEO Timothy R. Wright, CFO Peter M. Carlson, and CCO Rohit Kashyap will engage in fireside chats at the Credit Suisse 30th Annual Healthcare Conference on November 9, 2021, at 3:30 PM ET, and the Canaccord Genuity MedTech Forum on November 18, 2021, at 9:30 AM ET. Webcasts will be available via the company’s website. MiMedx specializes in regenerative medicine utilizing amniotic tissue for wound care and musculoskeletal conditions.